Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIK1003 first-in-human study in advanced solid tumors
2023-509230-19-00Phase 2Authorised
- Sponsor
- Eikon Therapeutics
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of eik1003 in Nonhematologic neoplasms, ovarian cancer, fallopian tube cancer (PFTC) and 4 more (5 arms), sponsored by Eikon Therapeutics. Primary endpoint: Safety and tolerability. Planned start Jul 2024; status: authorised.
02
Drugs
eik1003
03
Conditions
Nonhematologic neoplasmsovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)breast cancer
Beyond the preview
Go deeper on 2023-509230-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509230-19-00.